Key Highlights
- $24 million Series B funding co-led by Canaan and New Leaf Venture Partners.
- Funds to support Phase II trials of QLS‑111 in treating glaucoma and ocular hypertension.
- Unique approach targeting episcleral venous pressure (EVP) to improve intraocular pressure (IOP) control.
Source: Business Wire
Notable Quotes
- “We are grateful to have the support of this outstanding syndicate of leading life science investors, which will enable the continued development of our lead product, QLS‑111,” – Thurein Htoo, MS, MBA, Chief Executive Officer at Qlaris
- “Qlaris has the potential to demonstrate the importance of targeting EVP in the ongoing QLS‑111 Phase II trials and we look forward to the data from this innovative drug candidate,” – Wende Hutton, General Partner at Canaan
SoHC's Take
The successful closure of Qlaris Bio’s $24 million Series B financing round marks a significant milestone in the pursuit of advanced treatments for ophthalmic conditions. The company’s focus on targeting EVP, a critical yet often overlooked factor in IOP regulation, underscores a strategic approach that could redefine standards in glaucoma care. With this funding, Qlaris is well-poised to accelerate its clinical trials, potentially bringing a groundbreaking solution to market for conditions like NTG where treatment options are currently limited.
